{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T23:48:55Z","timestamp":1789429735202,"version":"build-2803163510"},"reference-count":86,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T00:00:00Z","timestamp":1776902400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["eBioMedicine"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.ebiom.2026.106288","type":"journal-article","created":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T13:09:47Z","timestamp":1778764187000},"page":"106288","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Sickle cell disease-associated pulmonary hypertension: an integrated framework linking pathologies, mechanisms, and clinical phenotypes"],"prefix":"10.1016","volume":"128","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9659-8278","authenticated-orcid":false,"given":"Florence","family":"Vallelian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6468-4013","authenticated-orcid":false,"given":"Dominik J.","family":"Schaer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benoit","family":"Lechartier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul W.","family":"Buehler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1743-8266","authenticated-orcid":false,"given":"David C.","family":"Irwin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ebiom.2026.106288_bib1","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1056\/NEJMoa1005565","article-title":"A hemodynamic study of pulmonary hypertension in sickle cell disease","volume":"365","author":"Parent","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ebiom.2026.106288_bib2","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1056\/NEJMoa035477","article-title":"Pulmonary hypertension as a risk factor for death in patients with sickle cell disease","volume":"350","author":"Gladwin","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ebiom.2026.106288_bib3","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1164\/rccm.202502-0353OC","article-title":"Cardiopulmonary hemodynamic determinants of long-term survival in sickle cell disease: insights from the ETENDARD study","volume":"211","author":"Savale","year":"2025","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.ebiom.2026.106288_bib4","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1146\/annurev-pathmechdis-012418-012838","article-title":"Pathophysiology of sickle cell disease","volume":"14","author":"Sundd","year":"2019","journal-title":"Annu Rev Pathol"},{"key":"10.1016\/j.ebiom.2026.106288_bib5","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1002\/ajh.21035","article-title":"Mutations and polymorphisms in hemoglobin genes and the risk of pulmonary hypertension and death in sickle cell disease","volume":"83","author":"Taylor","year":"2008","journal-title":"Am J Hematol"},{"key":"10.1016\/j.ebiom.2026.106288_bib6","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1002\/ajh.23232","article-title":"Genetic modifiers of sickle cell disease","volume":"87","author":"Steinberg","year":"2012","journal-title":"Am J Hematol"},{"key":"10.1016\/j.ebiom.2026.106288_bib7","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/S2213-2600(18)30409-0","article-title":"Genetic determinants of risk in pulmonary arterial hypertension: international genome-wide association studies and meta-analysis","volume":"7","author":"Rhodes","year":"2019","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.ebiom.2026.106288_bib8","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01324-2024","article-title":"Definition, classification and diagnosis of pulmonary hypertension","volume":"64","author":"Kovacs","year":"2024","journal-title":"Eur Respir J"},{"key":"10.1016\/j.ebiom.2026.106288_bib9","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01913-2018","article-title":"Haemodynamic definitions and updated clinical classification of pulmonary hypertension","volume":"53","author":"Simonneau","year":"2019","journal-title":"Eur Respir J"},{"key":"10.1016\/j.ebiom.2026.106288_bib10","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1097\/MCP.0000000000000200","article-title":"Pulmonary hypertension in sickle cell disease","volume":"21","author":"Fonseca","year":"2015","journal-title":"Curr Opin Pulm Med"},{"key":"10.1016\/j.ebiom.2026.106288_bib11","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1097\/MCP.0000000000000795","article-title":"The different facets of sickle cell disease-related pulmonary hypertension","volume":"27","author":"Prohaska","year":"2021","journal-title":"Curr Opin Pulm Med"},{"key":"10.1016\/j.ebiom.2026.106288_bib12","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00879-2022","article-title":"2022 ESC\/ERS guidelines for the diagnosis and treatment of pulmonary hypertension","volume":"61","author":"Humbert","year":"2023","journal-title":"Eur Respir J"},{"key":"10.1016\/j.ebiom.2026.106288_bib13","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1164\/rccm.201401-0065ST","article-title":"An official American Thoracic Society clinical practice guideline: diagnosis, risk stratification, and management of pulmonary hypertension of sickle cell disease","volume":"189","author":"Klings","year":"2014","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.ebiom.2026.106288_bib14","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1172\/JCI89741","article-title":"Intravascular hemolysis and the pathophysiology of sickle cell disease","volume":"127","author":"Kato","year":"2017","journal-title":"J Clin Invest"},{"key":"10.1016\/j.ebiom.2026.106288_bib15","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1038\/nm1202-799","article-title":"Cell-free hemoglobin limits nitric oxide bioavailability in sickle-cell disease","volume":"8","author":"Reiter","year":"2002","journal-title":"Nat Med"},{"key":"10.1016\/j.ebiom.2026.106288_bib16","doi-asserted-by":"crossref","DOI":"10.1002\/pul2.12362","article-title":"Diagnosis and management of chronic thromboembolic pulmonary hypertension (CTEPH) in sickle cell disease: a review","volume":"14","author":"Hersi","year":"2024","journal-title":"Pulm Circ"},{"key":"10.1016\/j.ebiom.2026.106288_bib17","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1053\/hupa.2002.128059","article-title":"Pulmonary hypertension in sickle cell hemoglobinopathy: a clinicopathologic study of 20 cases","volume":"33","author":"Haque","year":"2002","journal-title":"Hum Pathol"},{"key":"10.1016\/j.ebiom.2026.106288_bib18","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.5858\/2001-125-1436-PTAIPW","article-title":"Pulmonary thrombotic arteriopathy in patients with sickle cell disease","volume":"125","author":"Adedeji","year":"2001","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.ebiom.2026.106288_bib19","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1046\/j.1365-2141.2003.04594.x","article-title":"Causes of death in sickle cell disease: an autopsy study","volume":"123","author":"Manci","year":"2003","journal-title":"Br J Haematol"},{"key":"10.1016\/j.ebiom.2026.106288_bib20","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00585-2019","article-title":"Clinical phenotypes and outcomes of precapillary pulmonary hypertension of sickle cell disease","volume":"54","author":"Savale","year":"2019","journal-title":"Eur Respir J"},{"key":"10.1016\/j.ebiom.2026.106288_bib21","doi-asserted-by":"crossref","first-page":"2565","DOI":"10.1016\/S0140-6736(16)00647-4","article-title":"Cardiovascular complications and risk of death in sickle-cell disease","volume":"387","author":"Gladwin","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.ebiom.2026.106288_bib22","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1164\/rccm.200710-1606OC","article-title":"Pulmonary hypertension and cor pulmonale during severe acute chest syndrome in sickle cell disease","volume":"177","author":"Mekontso Dessap","year":"2008","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.ebiom.2026.106288_bib23","doi-asserted-by":"crossref","DOI":"10.1038\/nrdp.2018.10","article-title":"Sickle cell disease","volume":"4","author":"Kato","year":"2018","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.ebiom.2026.106288_bib24","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.tcm.2020.02.002","article-title":"Cardiovascular complications of sickle cell disease","volume":"31","author":"Sachdev","year":"2021","journal-title":"Trends Cardiovasc Med"},{"key":"10.1016\/j.ebiom.2026.106288_bib25","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1136\/heartjnl-2019-314810","article-title":"Sickle cell disease: at the crossroads of pulmonary hypertension and diastolic heart failure","volume":"106","author":"Wood","year":"2020","journal-title":"Heart"},{"key":"10.1016\/j.ebiom.2026.106288_bib26","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1056\/NEJMra0910283","article-title":"Hypoxia and inflammation","volume":"364","author":"Eltzschig","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ebiom.2026.106288_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.exphem.2025.104787","article-title":"Patterns of hemolysis, erythropoiesis, and iron distribution define unique disease trajectories in three mouse models of genetic anemia","volume":"147","author":"Dubach","year":"2025","journal-title":"Exp Hematol"},{"key":"10.1016\/j.ebiom.2026.106288_bib28","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1182\/blood.2022015596","article-title":"Hemolysis, free hemoglobin toxicity, and scavenger protein therapeutics","volume":"140","author":"Vallelian","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.ebiom.2026.106288_bib29","doi-asserted-by":"crossref","first-page":"3385","DOI":"10.1021\/bi002407m","article-title":"Kinetic and mechanistic studies of the NO\u2217-mediated oxidation of oxymyoglobin and oxyhemoglobin","volume":"40","author":"Herold","year":"2001","journal-title":"Biochemistry"},{"key":"10.1016\/j.ebiom.2026.106288_bib30","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1001\/jama.294.1.81","article-title":"Dysregulated arginine metabolism, hemolysis-associated pulmonary hypertension, and mortality in sickle cell disease","volume":"294","author":"Morris","year":"2005","journal-title":"JAMA"},{"key":"10.1016\/j.ebiom.2026.106288_bib31","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1007\/s00277-004-0983-3","article-title":"Plasma levels of asymmetric dimethylarginine (ADMA), an endogenous nitric oxide synthase inhibitor, are elevated in sickle cell disease","volume":"84","author":"Schnog","year":"2005","journal-title":"Ann Hematol"},{"key":"10.1016\/j.ebiom.2026.106288_bib32","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1016\/j.jchf.2024.02.013","article-title":"Asymmetric dimethylarginine and NT-proBNP levels provide synergistic information in pulmonary arterial hypertension","volume":"12","author":"Shafran","year":"2024","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.ebiom.2026.106288_bib33","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1164\/rccm.201510-2058OC","article-title":"Haptoglobin preserves vascular nitric oxide signaling during hemolysis","volume":"193","author":"Schaer","year":"2016","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.ebiom.2026.106288_bib34","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1182\/blood-2013-04-495887","article-title":"Heme triggers TLR4 signaling leading to endothelial cell activation and vaso-occlusion in murine sickle cell disease","volume":"123","author":"Belcher","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.ebiom.2026.106288_bib35","doi-asserted-by":"crossref","DOI":"10.1002\/prp2.392","article-title":"Revisiting the putative role of heme as a trigger of inflammation","volume":"6","author":"Vallelian","year":"2018","journal-title":"Pharmacol Res Perspect"},{"key":"10.1016\/j.ebiom.2026.106288_bib36","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/j.molmed.2020.02.004","article-title":"Haptoglobin therapeutics and compartmentalization of cell-free hemoglobin toxicity","volume":"26","author":"Buehler","year":"2020","journal-title":"Trends Mol Med"},{"key":"10.1016\/j.ebiom.2026.106288_bib37","doi-asserted-by":"crossref","first-page":"L765","DOI":"10.1152\/ajplung.00269.2018","article-title":"Depletion of haptoglobin and hemopexin promote hemoglobin-mediated lipoprotein oxidation in sickle cell disease","volume":"315","author":"Yalamanoglu","year":"2018","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"10.1016\/j.ebiom.2026.106288_bib38","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.bcmd.2017.05.009","article-title":"Oxidative pathways in the sickle cell and beyond","volume":"70","author":"Alayash","year":"2018","journal-title":"Blood Cells Mol Dis"},{"key":"10.1016\/j.ebiom.2026.106288_bib39","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1182\/blood.2020008455","article-title":"Excess heme upregulates heme oxygenase 1 and promotes cardiac ferroptosis in mice with sickle cell disease","volume":"139","author":"Menon","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.ebiom.2026.106288_bib40","article-title":"Ferroptosis as an emerging target in sickle cell disease","volume":"7","author":"Fortuna","year":"2024","journal-title":"Curr Res Toxicol"},{"key":"10.1016\/j.ebiom.2026.106288_bib41","first-page":"382","article-title":"Nrf2 sensitizes ferroptosis through l-2-hydroxyglutarate-mediated chromatin modifications in sickle cell disease","volume":"142","author":"Xi","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.ebiom.2026.106288_bib42","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1016\/j.freeradbiomed.2015.09.016","article-title":"Different target specificities of haptoglobin and hemopexin define a sequential protection system against vascular hemoglobin toxicity","volume":"89","author":"Deuel","year":"2015","journal-title":"Free Radic Biol Med"},{"key":"10.1016\/j.ebiom.2026.106288_bib43","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1038\/cdd.2013.113","article-title":"Mechanisms of haptoglobin protection against hemoglobin peroxidation triggered endothelial damage","volume":"20","author":"Schaer","year":"2013","journal-title":"Cell Death Differ"},{"key":"10.1016\/j.ebiom.2026.106288_bib44","doi-asserted-by":"crossref","first-page":"13S","DOI":"10.1016\/j.jacc.2004.02.029","article-title":"Cellular and molecular pathobiology of pulmonary arterial hypertension","volume":"43","author":"Humbert","year":"2004","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ebiom.2026.106288_bib45","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2025.118595","article-title":"Combined haptoglobin and hemopexin therapy for the treatment of cardiopulmonary dysfunction in sickle cell disease","volume":"192","author":"Lucero","year":"2025","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.ebiom.2026.106288_bib46","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.127860","article-title":"An Hb-mediated circulating macrophage contributing to pulmonary vascular remodeling in sickle cell disease","volume":"4","author":"Redinus","year":"2019","journal-title":"JCI Insight"},{"key":"10.1016\/j.ebiom.2026.106288_bib47","doi-asserted-by":"crossref","first-page":"5576","DOI":"10.1172\/JCI137282","article-title":"Hemolysis transforms liver macrophages into antiinflammatory erythrophagocytes","volume":"130","author":"Pfefferl\u00e9","year":"2020","journal-title":"J Clin Invest"},{"key":"10.1016\/j.ebiom.2026.106288_bib48","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2025-013063","article-title":"Stress-NRF2 response axis polarizes tumor macrophages and undermines immunotherapy","volume":"13","author":"Schaer","year":"2025","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.ebiom.2026.106288_bib49","doi-asserted-by":"crossref","DOI":"10.1172\/JCI174528","article-title":"Hemorrhage-activated NRF2 in tumor-associated macrophages drives cancer growth, invasion, and immunotherapy resistance","volume":"134","author":"Schaer","year":"2023","journal-title":"J Clin Invest"},{"key":"10.1016\/j.ebiom.2026.106288_bib50","doi-asserted-by":"crossref","first-page":"3805","DOI":"10.1182\/blood-2014-07-589283","article-title":"Circulating cell membrane microparticles transfer heme to endothelial cells and trigger vasoocclusions in sickle cell disease","volume":"125","author":"Camus","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.ebiom.2026.106288_bib51","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.adl4922","article-title":"Complement is activated in patients with acute chest syndrome caused by sickle cell disease and represents a therapeutic target","volume":"17","author":"Chonat","year":"2025","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.ebiom.2026.106288_bib52","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.96910","article-title":"Intravascular hemolysis activates complement via cell-free heme and heme-loaded microvesicles","volume":"3","author":"Merle","year":"2018","journal-title":"JCI Insight"},{"key":"10.1016\/j.ebiom.2026.106288_bib53","doi-asserted-by":"crossref","first-page":"3818","DOI":"10.1182\/blood-2013-10-529982","article-title":"Heme-induced neutrophil extracellular traps contribute to the pathogenesis of sickle cell disease","volume":"123","author":"Chen","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.ebiom.2026.106288_bib54","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1161\/CIRCRESAHA.116.304577","article-title":"Iron, inflammation, and early death in adults with sickle cell disease","volume":"116","author":"van Beers","year":"2015","journal-title":"Circ Res"},{"key":"10.1016\/j.ebiom.2026.106288_bib55","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1161\/CIRCRESAHA.108.182014","article-title":"Interleukin-6 overexpression induces pulmonary hypertension","volume":"104","author":"Steiner","year":"2009","journal-title":"Circ Res"},{"key":"10.1016\/j.ebiom.2026.106288_bib56","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.freeradbiomed.2019.08.009","article-title":"Free heme regulates placenta growth factor through NRF2-antioxidant response signaling","volume":"143","author":"Kapetanaki","year":"2019","journal-title":"Free Radic Biol Med"},{"key":"10.1016\/j.ebiom.2026.106288_bib57","doi-asserted-by":"crossref","first-page":"2014","DOI":"10.1182\/blood-2009-04-217950","article-title":"Placenta growth factor in sickle cell disease: association with hemolysis and inflammation","volume":"115","author":"Brittain","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.ebiom.2026.106288_bib58","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1038\/nrcardio.2010.145","article-title":"Mechanisms of vascular damage in obstructive sleep apnea","volume":"7","author":"Kohler","year":"2010","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.ebiom.2026.106288_bib59","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1182\/blood-2015-08-618561","article-title":"Pathophysiology and treatment of pulmonary hypertension in sickle cell disease","volume":"127","author":"Gordeuk","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.ebiom.2026.106288_bib60","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1080\/03630269.2023.2290507","article-title":"The prevalence of obstructive sleep apnea and associated symptoms among patients with sickle cell disease: a systematic review and meta-analysis","volume":"47","author":"Taherifard","year":"2023","journal-title":"Hemoglobin"},{"key":"10.1016\/j.ebiom.2026.106288_bib61","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1056\/NEJM200006223422502","article-title":"Causes and outcomes of the acute chest syndrome in sickle cell disease. National Acute Chest Syndrome Study Group","volume":"342","author":"Vichinsky","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ebiom.2026.106288_bib62","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1172\/JCI1932","article-title":"Tissue factor expression by endothelial cells in sickle cell anemia","volume":"101","author":"Solovey","year":"1998","journal-title":"J Clin Invest"},{"key":"10.1016\/j.ebiom.2026.106288_bib63","doi-asserted-by":"crossref","first-page":"3867","DOI":"10.1182\/bloodadvances.2019000916","article-title":"American society of hematology 2019 guidelines for sickle cell disease: cardiopulmonary and kidney disease","volume":"3","author":"Liem","year":"2019","journal-title":"Blood Adv"},{"key":"10.1016\/j.ebiom.2026.106288_bib64","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1164\/rccm.200208-967OC","article-title":"Arginine therapy: a new treatment for pulmonary hypertension in sickle cell disease?","volume":"168","author":"Morris","year":"2003","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.ebiom.2026.106288_bib65","first-page":"136","article-title":"Impact of oral -arginine supplementation on blood pressure dynamics in children with severe sickle cell vaso-occlusive crisis","volume":"11","author":"Onalo","year":"2021","journal-title":"Am J Cardiovasc Dis"},{"key":"10.1016\/j.ebiom.2026.106288_bib66","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1182\/blood-2010-09-306167","article-title":"Hospitalization for pain in patients with sickle cell disease treated with sildenafil for elevated TRV and low exercise capacity","volume":"118","author":"Machado","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.ebiom.2026.106288_bib67","doi-asserted-by":"crossref","first-page":"e345","DOI":"10.1016\/S2352-3026(24)00045-0","article-title":"Riociguat in patients with sickle cell disease and hypertension or proteinuria (STERIO-SCD): a randomised, double-blind, placebo controlled, phase 1-2 trial","volume":"11","author":"Gladwin","year":"2024","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.ebiom.2026.106288_bib68","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1111\/j.1365-2141.2010.08097.x","article-title":"Exercise capacity and haemodynamics in patients with sickle cell disease with pulmonary hypertension treated with bosentan: results of the ASSET studies","volume":"149","author":"Barst","year":"2010","journal-title":"Br J Haematol"},{"key":"10.1016\/j.ebiom.2026.106288_bib69","doi-asserted-by":"crossref","first-page":"e163","DOI":"10.3324\/haematol.2015.131227","article-title":"Prostacyclin-analog therapy in sickle cell pulmonary hypertension","volume":"102","author":"Weir","year":"2017","journal-title":"Haematologica"},{"key":"10.1016\/j.ebiom.2026.106288_bib70","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1097\/SHK.0000000000002593","article-title":"Prostacyclin-analog therapy for pulmonary vascular dysfunction during severe acute chest syndrome in sickle cell disease","volume":"64","author":"Lopinto","year":"2025","journal-title":"Shock"},{"key":"10.1016\/j.ebiom.2026.106288_bib71","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1182\/blood-2014-12-614370","article-title":"Chronic transfusion therapy improves but does not normalize systemic and pulmonary vasculopathy in sickle cell disease","volume":"126","author":"Detterich","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.ebiom.2026.106288_bib72","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00272-2018","article-title":"Chronic blood exchange transfusions in the management of pre-capillary pulmonary hypertension complicating sickle cell disease","volume":"52","author":"Turpin","year":"2018","journal-title":"Eur Respir J"},{"key":"10.1016\/j.ebiom.2026.106288_bib73","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1038\/s41409-021-01298-7","article-title":"Stable to improved cardiac and pulmonary function in children with high-risk sickle cell disease following haploidentical stem cell transplantation","volume":"56","author":"Friedman","year":"2021","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.ebiom.2026.106288_bib74","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1046\/j.1365-2141.2002.03274.x","article-title":"Nitric oxide donor properties of hydroxyurea in patients with sickle cell disease","volume":"116","author":"Gladwin","year":"2002","journal-title":"Br J Haematol"},{"key":"10.1016\/j.ebiom.2026.106288_bib75","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2117175","article-title":"Biologic and clinical efficacy of LentiGlobin for sickle cell disease","volume":"386","author":"Kanter","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ebiom.2026.106288_bib76","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1056\/NEJMoa2309676","article-title":"Exagamglogene autotemcel for severe sickle cell disease","volume":"390","author":"Frangoul","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ebiom.2026.106288_bib77","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.freeradbiomed.2025.01.045","article-title":"Targeting lung heme iron by aerosol hemopexin adminstration in sickle cell disease pulmonary hypertension","volume":"229","author":"Lucero","year":"2025","journal-title":"Free Radic Biol Med"},{"key":"10.1016\/j.ebiom.2026.106288_bib78","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.freeradbiomed.2021.08.238","article-title":"Hemopexin dosing improves cardiopulmonary dysfunction in murine sickle cell disease","volume":"175","author":"Buehler","year":"2021","journal-title":"Free Radic Biol Med"},{"key":"10.1016\/j.ebiom.2026.106288_bib79","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1182\/bloodadvances.2020002754","article-title":"PPAR\u03b3 increases HUWE1 to attenuate NF-\u03baB\/p65 and sickle cell disease with pulmonary hypertension","volume":"5","author":"Jang","year":"2021","journal-title":"Blood Adv"},{"key":"10.1016\/j.ebiom.2026.106288_bib80","doi-asserted-by":"crossref","first-page":"L1150","DOI":"10.1152\/ajplung.00302.2018","article-title":"Vascular TSP1-CD47 signaling promotes sickle cell-associated arterial vasculopathy and pulmonary hypertension in mice","volume":"316","author":"Novelli","year":"2019","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"10.1016\/j.ebiom.2026.106288_bib81","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1097\/FJC.0000000000000570","article-title":"New nitric oxide donor NCX 1443: therapeutic effects on pulmonary hypertension in the SAD mouse model of sickle cell disease","volume":"71","author":"Abid","year":"2018","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.ebiom.2026.106288_bib82","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1165\/rcmb.2017-0292OC","article-title":"Nitric oxide-independent soluble guanylate cyclase activation improves vascular function and cardiac remodeling in sickle cell disease","volume":"58","author":"Potoka","year":"2018","journal-title":"Am J Respir Cell Mol Biol"},{"key":"10.1016\/j.ebiom.2026.106288_bib83","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1213\/ANE.0000000000001378","article-title":"Arginase inhibition reverses endothelial dysfunction, pulmonary hypertension, and vascular stiffness in transgenic sickle cell mice","volume":"123","author":"Steppan","year":"2016","journal-title":"Anesth Analg"},{"key":"10.1016\/j.ebiom.2026.106288_bib84","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1096\/fj.07-098921","article-title":"Protective effects of phosphodiesterase-4 (PDE-4) inhibition in the early phase of pulmonary arterial hypertension in transgenic sickle cell mice","volume":"22","author":"De Franceschi","year":"2008","journal-title":"FASEB J"},{"issue":"9","key":"10.1016\/j.ebiom.2026.106288_bib85","doi-asserted-by":"crossref","first-page":"3229","DOI":"10.1182\/bloodadvances.2025018680","article-title":"Ferroportin inhibition attenuates pulmonary hypertension in hypoxic sickle cell disease mice","volume":"10","author":"Lucero","year":"2026","journal-title":"Blood Adv"},{"key":"10.1016\/j.ebiom.2026.106288_bib86","doi-asserted-by":"crossref","first-page":"870","DOI":"10.3324\/haematol.2015.124586","article-title":"Dietary \u03c9-3 fatty acids protect against vasculopathy in a transgenic mouse model of sickle cell disease","volume":"100","author":"Kalish","year":"2015","journal-title":"Haematologica"}],"container-title":["eBioMedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352396426001702?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352396426001702?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T08:46:30Z","timestamp":1781081190000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352396426001702"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":86,"alternative-id":["S2352396426001702"],"URL":"https:\/\/doi.org\/10.1016\/j.ebiom.2026.106288","relation":{},"ISSN":["2352-3964"],"issn-type":[{"value":"2352-3964","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Sickle cell disease-associated pulmonary hypertension: an integrated framework linking pathologies, mechanisms, and clinical phenotypes","name":"articletitle","label":"Article Title"},{"value":"eBioMedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ebiom.2026.106288","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"106288"}}